Clinical Trials Logo

Measles; Mumps; Rubella clinical trials

View clinical trials related to Measles; Mumps; Rubella.

Filter by:
  • None
  • Page 1

NCT ID: NCT06399003 Not yet recruiting - Clinical trials for Measles-Mumps-Rubella

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Start date: June 20, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.'s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9-11 Months of Age.

NCT ID: NCT02184572 Completed - Clinical trials for Measles-Mumps-Rubella Vaccine

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Start date: August 25, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.

NCT ID: NCT01621802 Completed - Clinical trials for Measles-Mumps-Rubella

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Start date: June 21, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when given as a second dose to children four to six years of age.